Response to booster hepatitis B vaccines in liver-transplanted children primarily vaccinated in infancy

Transplantation

Volumn 86, Issue 11, 2008, Pages 1531-1535

  Ni, Yen Hsuan ^a   Ho, Ming Chih ^a   Wu, Jia Feng ^a   Chen, Huey Ling ^a   Wu, Yao Ming ^a   Hu, Rey Heng ^a   Lee, Po Huang ^a,b   Chang, Mei Hwei ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Booster vaccine; Hepatitis B virus; Liver transplantation enzyme linked immunospot

Indexed keywords

CYCLOSPORIN; GAMMA INTERFERON; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; INTERLEUKIN 5; RECOMBINANT HEPATITIS B VACCINE; TACROLIMUS; HEPATITIS B VACCINE;

ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG BLOOD LEVEL; FEMALE; HEPATITIS B; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; SEX DIFFERENCE; TH1 CELL; TH2 CELL; VACCINATION; CHILD; HELPER CELL; IMMUNIZATION; INFANT; LIVER DISEASE; METABOLISM; PRESCHOOL CHILD; VIROLOGY;

CHILD; CHILD, PRESCHOOL; FEMALE; HEPATITIS B; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION SCHEDULE; INFANT; INTERFERON-GAMMA; INTERLEUKIN-5; LIVER DISEASES; LIVER TRANSPLANTATION; MALE; T-LYMPHOCYTES, HELPER-INDUCER; VACCINATION;

EID: 58149341596     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318189064c     Document Type: Article

References (23)

1. Ambrosino DM, Molrine DC. Critical appraisalof immunization strategies for prevention of infection in the compromised host. Hematol Oncol Clin North Am 1993; 7: 1027.
2. Stark K, Gunther M, Schonfeld C, et al. Immunizations in solid-organ transplant recipients. Lancet 2002; 359: 957.
3. Blumberg EA, Brozena SC, Stutman P, et al. Immunogenicity of pneumo-coccal vaccine in heart transplant recipients. Clin Infect Dis 2001; 32: 307.
4. Ni YH, Chang MH, Huang LM, et al. Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after universal hepatitis B vaccination. Ann Intern Med 2001; 135: 796.
5. Ni YH, Huang LM, Chang MH,etal. Two decadesofuniversal hepatitis B vaccination in Taiwan: Impact and implication for future strategies. Gastroenterology 2007; 132: 1287.
6. Hsu HM, Lu CF, Lee SC, et al. Seroepidemiologic survey for hepatitis B virus infection in Taiwan: The effect of hepatitis B mass immunization. J Infect Dis 1999; 179: 367.
7. Huang LM, Chiang BL, Lee CY, etal. Long-term response to hepatitis B vaccination and response to booster in children born to mothers with hepatitis B e antigen. Hepatology 1999; 29: 954.
8. Lu CY, Chiang BL, Chi WK, et al. Waning immunity to plasma-derived hepatitisBvaccine and the need for boosters fifteen years after neonatal vaccination. Hepatology 2004; 40: 1415.
9. Shih HH, Chang MH, Hsu HY, et al. Long-term immune response of universal hepatitis B vaccination in infancy: A community-based study in Taiwan. Pediatr Infect Dis J 1999; 18: 427.
10. Lin YC, Chang MH, Ni YH, et al. Long-term immunogenicity and efficacy of universal hepatitis B virus vaccination in Taiwan. J Infect Dis 2003; 187: 134.
11. Hadler SC, Francis DP, Maynard JE, et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med 1986; 315: 209.
12. Lee CY, Huang LM, Chang MH, et al. The protective efficacyof recombinant hepatitis B vaccine in newborn infants of hepatitis B e antigenpositive- hepatitis B surface antigen carrier mothers. Pediatr Infect Dis J 1991; 10: 299.
13. Duca P, Del Pont JM, D'Agostino D. Successful immune response to a recombinant hepatitis B vaccine in children after liver transplantation. J Pediatr Gastroenterol Nutr 2001; 32: 168.
14. Lin CC, Chen CL, Concejero A, et al. Active immunization to prevent de novo hepatitis B virus infection in pediatric live donor liver recipients. Am J Transplant 2007; 7: 195.
15. Fujihashi K, McGhee JR, Beagley KW,etal. Cytokine-specific ELISPOT assay. Single cell analysis of IL-2, IL-4 and IL-6 producing cells. J Immunol Methods 1993; 160: 181.
16. Sarawar SR, Doherty PC. Concurrent production of interleukin-2, interleukin-10, and gamma interferon in the regional lymph nodes of mice with influenza pneumonia. J Virol 1994; 68: 3112.
17. Jack AD, Hall AJ, Maine N, et al. What level of hepatitis B antibody is protective? J Infect Dis 1999; 179: 489.
18. Li Volti S, Di Gregorio F, Romeo MA, et al. Immune status and the immune response to hepatitis B virus vaccine in thalassemic patients after allogeneic bone marrow transplantation. Bone Marrow Transplant 1997; 19: 157.
19. Fang JW, Lai CL, Chung HT, et al. Female-children respond to recombinant hepatitis-b vaccine with a higher titer than male. J Trop Pediatr 1994; 40: 104.
20. Chang SH, Suh KS, Yi NJ, et al. Active immunization against de novo hepatitis B virus infection in pediatric patients after liver transplantation. Hepatology 2003; 37: 1329.
21. Bauer T, Gunther M, Bienzle U, et al. Vaccination against hepatitis B in liver transplant recipients: Pilot analysis of cellular immune response shows evidence of HBsAg-specific regulatory T cells. Liver Transplant 2007; 13: 434.
22. Hsu HY, Chang MH, Ho HN, et al. Association of HLA-DR14-DR52 with low responsiveness to hepatitis B vaccine in Chinese residents in Taiwan. Vaccine 1993; 11: 1437.
23. Kruskall MS, Alper CA, Awdeh Z, et al. The immune response to hepatitis B vaccine in humans: Inheritance patterns in families. J Exp Med 1992; 175: 495.